MOU WITH PANTAI PREMIER PATHOLOGY
MOU WITH PANTAI PREMIER PATHOLOGY GIVES AMMETLIFE CUSTOMERS GREATER ACCESS TO AFFORDABLE GENOMIC TESTING FOR CANCER
KUALA LUMPUR, Nov 9 (Bernama) -- AmMetLife Insurance Berhad (“AmMetLife”) and Pantai Premier Pathology Sdn. Bhd. (“Pantai Premier Pathology”) have signed a Memorandum of Understanding (MOU) extending their existing collaboration for two more years. Through this collaboration, AmMetLife’s medical plan customers will be able to access preferential rates when undergoing genomic testing for cancer at Pantai Premier Pathology’s network of 14 medical facilities across Malaysia.
The MOU covers 47 different tests, including BRCA for breast and ovarian cancer as well as EGFR for lung cancer, which can help to assist physicians in making more informed treatment decisions for cancer patients.
The MOU was signed by Lee Jiau Jiunn, Chief Executive Officer, AmMetLife and Hareeff Muhammed, Chief Executive Officer, Pantai Premier Pathology during a virtual ceremony attended by senior management and employees of both companies.
Comments